Drug updated on 12/11/2024
Dosage Form | Tablet (oral; linagliptin/ metformin; 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1,000 mg) |
Drug Class | Dipeptidyl peptidase-4 (DPP-4) inhibitors and biguanides |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Latest News
Summary
- This summary is based on the review of two randomized controlled trial(s). [1-2]
- In patients with impaired glucose tolerance, the linagliptin + metformin (LM) group demonstrated a significant reduction in glucose levels during oral glucose tolerance test (OGTT) (area under the glucose curve (AUCgluc) (0-120min): -4425 ± 871 vs. -1116 ± 1104 mg/dl/120 min, p < 0.001) and improved pancreatic beta-cell function (2.3 ± 0.23 vs. 1.7 ± 0.27, p = 0.001) compared to metformin alone.
- Over 24 months, patients with prediabetes and two additional type 2 diabetes (T2D) risk factors in the LM group had a higher probability of regression to normoglycemia (odds ratio (OR) 3.26, 95% confidence interval (CI) 1.55-6.84) and a lower incidence of T2D (hazard ratio (HR) 4.0, 95% CI 1.24-13.04, p = 0.020) than those on metformin alone.
- The LM group showed greater improvements in pancreatic beta-cell function, with the disposition index increasing from 1.31 (95% CI: 1.14-1.49) to 2.41 (95% CI: 2.10-2.72) at 6 months and to 2.07 (95% CI: 1.82-2.31) at 24 months, compared to smaller increases in the metformin group (p < 0.05).
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Jentadueto (linagliptin and metformin hydrochloride) Prescribing Information. | 2023 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle | 33Subjects F: 76% M: 24% | 2021 | Scientific Reports |
The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial | 144Subjects F: 61% M: 39% | 2020 | Metabolism |
Sex Distribution:
F:76%
M:24%
33Subjects
Year:
2021
Source:Scientific Reports
Sex Distribution:
F:61%
M:39%
144Subjects
Year:
2020
Source:Metabolism
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline | 2023 | The Journal of Clinical Endocrinology and Metabolism |
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update | 2023 | Endocrine Practice |